Cargando…
Clinical effects of durability of immunosuppression in virologically suppressed ART-initiating persons with HIV in Latin America. A retrospective cohort study
BACKGROUND: Clinical outcomes are rarely studied in virologically suppressed people living with HIV (PWH) and incomplete CD4 recovery. To explore whether time living with severe immunosuppression predict clinical outcomes better than baseline or time updated CD4, we estimated the association between...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121860/ https://www.ncbi.nlm.nih.gov/pubmed/35602655 http://dx.doi.org/10.1016/j.lana.2021.100175 |
_version_ | 1784711231942164480 |
---|---|
author | Caro-Vega, Yanink Rebeiro, Peter F. Shepherd, Bryan E. Belaunzarán-Zamudio, Pablo F. Crabtree-Ramirez, Brenda Cesar, Carina Luz, Paula Mendes Cortes, Claudia P. Padget, Denis Gotuzzo, Eduardo McGowan, Catherine C. Sierra-Madero, Juan G. |
author_facet | Caro-Vega, Yanink Rebeiro, Peter F. Shepherd, Bryan E. Belaunzarán-Zamudio, Pablo F. Crabtree-Ramirez, Brenda Cesar, Carina Luz, Paula Mendes Cortes, Claudia P. Padget, Denis Gotuzzo, Eduardo McGowan, Catherine C. Sierra-Madero, Juan G. |
author_sort | Caro-Vega, Yanink |
collection | PubMed |
description | BACKGROUND: Clinical outcomes are rarely studied in virologically suppressed people living with HIV (PWH) and incomplete CD4 recovery. To explore whether time living with severe immunosuppression predict clinical outcomes better than baseline or time updated CD4, we estimated the association between cumulative percentage of time with CD4 <200 cells/µL during viral suppression (VS) (%t(CD4<200)), and mortality and comorbidities during 2000-2019. METHODS: In a retrospective cohort analysis, we followed PWH initiating ART in Latin America from first VS (HIV-RNA<200 copies/µL) to death, virological failure or loss to follow-up. We fit Cox models to estimate risk of death and/or AIDS-defining and serious non-AIDS-defining events (ADE and SNADE -cancer, cardiovascular, liver, and renal diseases) by %t(CD4<200) (continuous variable). We predicted survival probabilities for each event and calculated risks of hypothetical cases of different %t(CD4<200). FINDINGS: In 8,369 patients with 34·9 months of follow-up (median, IQR: 16·7, 69·1), 4,274 (51%) started ART with CD4<200 cells/µL. Median %t(CD4<200) was 0% (IQR: 0, 15%). We identified 195 (2·3%) deaths and 584 (7·2%) patients with ADE/SNADE. For an increased %t(CD4<200) of 15% (e.g., 15% vs. 0%), the adjusted relative hazard (aHR) of death was 1·27 (95% confidence interval [CI]: 1·19 – 1·35), of ADE/SNADE was 1·13 (95%CI: 1·09 – 1·17), of SNADE was 0·96 (95%CI: 0·89 – 1·02) and of death/ADE/SNADE was 1·11 (95%CI: 1·07 – 1·14). Estimates were similar after adjusting for time updated CD4 count. INTERPRETATION: In virologically suppressed PWH, increased time living with severe immunosuppression had an increased risk of death and ADE/SNADE in this Latin American cohort, independently of time updated CD4 count. FUNDING: This work was supported by the NIH-funded Caribbean, Central and South America network for HIV epidemiology (CCASAnet, U01AI069923), a member cohort of the International Epidemiologic Databases to Evaluate AIDS (leDEA). This award is funded by the following institutes: Eunice Kennedy Shriver National Institute Of Child Health & Human Development (NICHD), National Cancer Institute (NCI), National Institute Of Allergy And Infectious Diseases (NIAID), National Institute Of Mental Health (NIMH), the National Heart, Lung, and Blood Institute (NHLBI), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and the Fogarty International Center (FIC). Specific funding was provided from the Fogarty International Center (FIC) for lead author, Yanink Caro-Vega, for the Fogarty-IeDEA Mentorship Program (FIMP). |
format | Online Article Text |
id | pubmed-9121860 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-91218602022-05-20 Clinical effects of durability of immunosuppression in virologically suppressed ART-initiating persons with HIV in Latin America. A retrospective cohort study Caro-Vega, Yanink Rebeiro, Peter F. Shepherd, Bryan E. Belaunzarán-Zamudio, Pablo F. Crabtree-Ramirez, Brenda Cesar, Carina Luz, Paula Mendes Cortes, Claudia P. Padget, Denis Gotuzzo, Eduardo McGowan, Catherine C. Sierra-Madero, Juan G. Lancet Reg Health Am Articles BACKGROUND: Clinical outcomes are rarely studied in virologically suppressed people living with HIV (PWH) and incomplete CD4 recovery. To explore whether time living with severe immunosuppression predict clinical outcomes better than baseline or time updated CD4, we estimated the association between cumulative percentage of time with CD4 <200 cells/µL during viral suppression (VS) (%t(CD4<200)), and mortality and comorbidities during 2000-2019. METHODS: In a retrospective cohort analysis, we followed PWH initiating ART in Latin America from first VS (HIV-RNA<200 copies/µL) to death, virological failure or loss to follow-up. We fit Cox models to estimate risk of death and/or AIDS-defining and serious non-AIDS-defining events (ADE and SNADE -cancer, cardiovascular, liver, and renal diseases) by %t(CD4<200) (continuous variable). We predicted survival probabilities for each event and calculated risks of hypothetical cases of different %t(CD4<200). FINDINGS: In 8,369 patients with 34·9 months of follow-up (median, IQR: 16·7, 69·1), 4,274 (51%) started ART with CD4<200 cells/µL. Median %t(CD4<200) was 0% (IQR: 0, 15%). We identified 195 (2·3%) deaths and 584 (7·2%) patients with ADE/SNADE. For an increased %t(CD4<200) of 15% (e.g., 15% vs. 0%), the adjusted relative hazard (aHR) of death was 1·27 (95% confidence interval [CI]: 1·19 – 1·35), of ADE/SNADE was 1·13 (95%CI: 1·09 – 1·17), of SNADE was 0·96 (95%CI: 0·89 – 1·02) and of death/ADE/SNADE was 1·11 (95%CI: 1·07 – 1·14). Estimates were similar after adjusting for time updated CD4 count. INTERPRETATION: In virologically suppressed PWH, increased time living with severe immunosuppression had an increased risk of death and ADE/SNADE in this Latin American cohort, independently of time updated CD4 count. FUNDING: This work was supported by the NIH-funded Caribbean, Central and South America network for HIV epidemiology (CCASAnet, U01AI069923), a member cohort of the International Epidemiologic Databases to Evaluate AIDS (leDEA). This award is funded by the following institutes: Eunice Kennedy Shriver National Institute Of Child Health & Human Development (NICHD), National Cancer Institute (NCI), National Institute Of Allergy And Infectious Diseases (NIAID), National Institute Of Mental Health (NIMH), the National Heart, Lung, and Blood Institute (NHLBI), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and the Fogarty International Center (FIC). Specific funding was provided from the Fogarty International Center (FIC) for lead author, Yanink Caro-Vega, for the Fogarty-IeDEA Mentorship Program (FIMP). Elsevier 2022-01-13 /pmc/articles/PMC9121860/ /pubmed/35602655 http://dx.doi.org/10.1016/j.lana.2021.100175 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Articles Caro-Vega, Yanink Rebeiro, Peter F. Shepherd, Bryan E. Belaunzarán-Zamudio, Pablo F. Crabtree-Ramirez, Brenda Cesar, Carina Luz, Paula Mendes Cortes, Claudia P. Padget, Denis Gotuzzo, Eduardo McGowan, Catherine C. Sierra-Madero, Juan G. Clinical effects of durability of immunosuppression in virologically suppressed ART-initiating persons with HIV in Latin America. A retrospective cohort study |
title | Clinical effects of durability of immunosuppression in virologically suppressed ART-initiating persons with HIV in Latin America. A retrospective cohort study |
title_full | Clinical effects of durability of immunosuppression in virologically suppressed ART-initiating persons with HIV in Latin America. A retrospective cohort study |
title_fullStr | Clinical effects of durability of immunosuppression in virologically suppressed ART-initiating persons with HIV in Latin America. A retrospective cohort study |
title_full_unstemmed | Clinical effects of durability of immunosuppression in virologically suppressed ART-initiating persons with HIV in Latin America. A retrospective cohort study |
title_short | Clinical effects of durability of immunosuppression in virologically suppressed ART-initiating persons with HIV in Latin America. A retrospective cohort study |
title_sort | clinical effects of durability of immunosuppression in virologically suppressed art-initiating persons with hiv in latin america. a retrospective cohort study |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121860/ https://www.ncbi.nlm.nih.gov/pubmed/35602655 http://dx.doi.org/10.1016/j.lana.2021.100175 |
work_keys_str_mv | AT carovegayanink clinicaleffectsofdurabilityofimmunosuppressioninvirologicallysuppressedartinitiatingpersonswithhivinlatinamericaaretrospectivecohortstudy AT rebeiropeterf clinicaleffectsofdurabilityofimmunosuppressioninvirologicallysuppressedartinitiatingpersonswithhivinlatinamericaaretrospectivecohortstudy AT shepherdbryane clinicaleffectsofdurabilityofimmunosuppressioninvirologicallysuppressedartinitiatingpersonswithhivinlatinamericaaretrospectivecohortstudy AT belaunzaranzamudiopablof clinicaleffectsofdurabilityofimmunosuppressioninvirologicallysuppressedartinitiatingpersonswithhivinlatinamericaaretrospectivecohortstudy AT crabtreeramirezbrenda clinicaleffectsofdurabilityofimmunosuppressioninvirologicallysuppressedartinitiatingpersonswithhivinlatinamericaaretrospectivecohortstudy AT cesarcarina clinicaleffectsofdurabilityofimmunosuppressioninvirologicallysuppressedartinitiatingpersonswithhivinlatinamericaaretrospectivecohortstudy AT luzpaulamendes clinicaleffectsofdurabilityofimmunosuppressioninvirologicallysuppressedartinitiatingpersonswithhivinlatinamericaaretrospectivecohortstudy AT cortesclaudiap clinicaleffectsofdurabilityofimmunosuppressioninvirologicallysuppressedartinitiatingpersonswithhivinlatinamericaaretrospectivecohortstudy AT padgetdenis clinicaleffectsofdurabilityofimmunosuppressioninvirologicallysuppressedartinitiatingpersonswithhivinlatinamericaaretrospectivecohortstudy AT gotuzzoeduardo clinicaleffectsofdurabilityofimmunosuppressioninvirologicallysuppressedartinitiatingpersonswithhivinlatinamericaaretrospectivecohortstudy AT mcgowancatherinec clinicaleffectsofdurabilityofimmunosuppressioninvirologicallysuppressedartinitiatingpersonswithhivinlatinamericaaretrospectivecohortstudy AT sierramaderojuang clinicaleffectsofdurabilityofimmunosuppressioninvirologicallysuppressedartinitiatingpersonswithhivinlatinamericaaretrospectivecohortstudy |